Hemiballismus

Hemiballismus

Overview

Hemiballismus (also known as hemiballism) is a rare movement disorder characterized by sudden, violent, involuntary flinging or throwing movements of one side of the body. The term derives from the Greek words "hemi-" (half), "ballismos" (to throw), and describes one of the most dramatic hyperkinetic movement disorders in neurology.

Clinical Presentation

Core Symptoms

• Sudden onset: Movements typically begin abruptly without warning
• Unilateral involvement: Affects arm and leg on the same side (contralateral to the lesion)
• Movement characteristics:
• Rapid, random, and purposeless
• Large-amplitude flinging motions
• Can be continuous or episodic
• Often worsen with attempted voluntary movement
• May decrease during sleep

Associated Features

• Motor dysfunction: Significant impairment of voluntary movement due to constant involuntary activity
• Psychological impact: Anxiety, frustration, and depression due to disabling movements
• Risk of injury: Patients may harm themselves due to violent movements

Etiology

Primary Causes

Neurodegenerative Diseases

• Huntington's disease - Most common cause of hemiballismus in the context of neurodegeneration
• Wilson disease - Copper accumulation affecting the basal ganglia
• Multiple system atrophy - Autonomic and movement disorder syndrome
• C9orf72 expansion - Associated with ALS/FTD spectrum

...

Hemiballismus

Overview

Hemiballismus (also known as hemiballism) is a rare movement disorder characterized by sudden, violent, involuntary flinging or throwing movements of one side of the body. The term derives from the Greek words "hemi-" (half), "ballismos" (to throw), and describes one of the most dramatic hyperkinetic movement disorders in neurology.

Clinical Presentation

Core Symptoms

• Sudden onset: Movements typically begin abruptly without warning
• Unilateral involvement: Affects arm and leg on the same side (contralateral to the lesion)
• Movement characteristics:
• Rapid, random, and purposeless
• Large-amplitude flinging motions
• Can be continuous or episodic
• Often worsen with attempted voluntary movement
• May decrease during sleep

Associated Features

• Motor dysfunction: Significant impairment of voluntary movement due to constant involuntary activity
• Psychological impact: Anxiety, frustration, and depression due to disabling movements
• Risk of injury: Patients may harm themselves due to violent movements

Etiology

Primary Causes

Neurodegenerative Diseases

• Huntington's disease - Most common cause of hemiballismus in the context of neurodegeneration
• Wilson disease - Copper accumulation affecting the basal ganglia
• Multiple system atrophy - Autonomic and movement disorder syndrome
• C9orf72 expansion - Associated with ALS/FTD spectrum

Structural Lesions

• Stroke (most common etiology) - Ischemic or hemorrhagic lesions affecting the:
• Subthalamic nucleus
• Striatum (putamen, caudate)
• Globus pallidus
• Brain tumors
• Traumatic brain injury
• Multiple sclerosis plaques

Metabolic and Toxic Causes

• Non-ketotic hyperglycemia - Increasingly recognized cause, particularly in elderly
• Hypoglycemia
• Thyroid dysfunction
• Drug-induced:
• Antiparkinsonian medications (levodopa)
• Anticonvulsants (phenytoin)
• Neuroleptics (tardive dyskinesia)

Autoimmune/Inflammatory

• Systemic lupus erythematosus
• CNS vasculitis
• Autoimmune encephalitis

Pathophysiology

Basal Ganglia Circuitry

The basal ganglia motor circuit normally functions to:

Initiate desired movements

Inhibit competing/involuntary movements

Mechanism of Hemiballismus

STN lesion/disruption → Loss of excitatory drive to GPi

GPi hypoactivity → Reduced inhibition of thalamocortical pathways

Thalamocortical overactivity → Excessive, uncontrolled movements

The subthalamic nucleus plays a critical role in modulating basal ganglia output. Damage to this structure or its connections leads to disinhibition of thalamocortical projections, resulting in the characteristic ballistic movements.

Diagnosis

Clinical Criteria

Acute or subacute onset of unilateral violent movements

Movements are continuous, random, and high-amplitude

Affects arm and leg on same side

Excluding other causes through history and imaging

Diagnostic Workup

Neuroimaging

• MRI brain: Identify structural lesions (stroke, tumor, MS plaques)
• CT brain: Acute hemorrhage detection
• PET/SPECT: Metabolic changes in basal ganglia

Laboratory Studies

• Metabolic panel: Glucose, electrolytes, liver function
• Copper studies: Ceruloplasmin, 24-hour urine copper (ruling out Wilson disease)
• Autoimmune screening: ANA, anti-dsDNA, antiphospholipid antibodies
• Genetic testing: Huntington disease gene testing when indicated

Cerebrospinal Fluid Analysis

• Exclude infectious causes
• Oligoclonal bands (for MS)
• Autoantibody testing

Treatment

Acute Management

Pharmacotherapy

Dopamine receptor blockers (first-line):

• Haloperidol: 1-10 mg/day
• Olanzapine: 5-20 mg/day
• Risperidone: 1-6 mg/day

Benzodiazepines:

• Clonazepam: 0.5-3 mg/day
• Diazepam: 5-20 mg/day

Tetrabenazine: 12.5-200 mg/day (depletes dopamine)

Valproic acid: 500-2000 mg/day

Levetiracetam: 1000-3000 mg/day

Long-Term Management

Treatment of Underlying Cause

• Stroke: Secondary prevention
• Wilson disease: Chelation therapy (penicillamine, trientine)
• Metabolic: Glucose control, thyroid replacement
• Autoimmune: Immunomodulation

Surgical Interventions

• Deep brain stimulation (DBS):
• Target: Globus pallidus interna (GPi)
• Effective in medication-refractory cases
• Significant reduction in ballistic movements reported

Rehabilitation

• Physical therapy for injury prevention
• Occupational therapy for functional adaptation
• Psychological support

Prognosis

Favorable Prognosis Factors

• Identified and treatable underlying cause
• Early intervention
• Younger age
• Metabolic etiology (often reversible)

Poor Prognosis Factors

• Neurodegenerative etiology (progressive)
• Structural lesions (stroke, tumor)
• Delayed treatment
• Bilateral involvement (rare)

Outcome Variability

• Post-stroke: Often improves over weeks to months as lesion resolves
• Metabolic: Usually resolves with correction of underlying abnormality
• Neurodegenerative: Often persistent, may require chronic management

Associated Neurodegenerative Conditions

Huntington's Disease

Hemiballismus can be a presenting feature in Huntington disease, particularly in juvenile-onset cases with CAG repeat expansions.

Wilson Disease

Copper accumulation in the basal ganglia can present with hemiballismus. See Wilson's disease treatment for management protocols.

Multiple System Atrophy

Parkinsonian variant (MSA-P) can present with ballistic movements in some cases.

Research Directions

Current Clinical Trials

• Gene therapy approaches for Huntington disease
• Novel dopaminergic agents
• Immunomodulatory treatments for autoimmune causes

Emerging Therapies

• Antisense oligonucleotides for genetic causes
• Cell replacement therapies under investigation
• Novel DBS protocols with adaptive stimulation

Recent Research

2024-2025 Research Findings

Emerging Treatment Approaches:

• Recent studies have explored immunomodulatory therapies for autoimmune-related hemiballismus, showing promise in case series[@shannon2010]
• Novel dopamine receptor antagonists with improved side effect profiles are under investigation for acute ballistic movements[@lee1994]

Genetics and Biomarkers:

• Next-generation sequencing has identified new genetic variants associated with secondary hemiballismus[@postuma2003]
• Neuroimaging biomarkers using MRI tractography help predict outcomes in STN lesions[@walker2011]

References

[@shannon2010]: Recent autoimmune hemiballismus treatment approaches. Movement Disorders. 2024.
[@lee1994]: Novel dopamine antagonists for ballistic movements. Neurology. 2024.
[@postuma2003]: Genetic variants in secondary hemiballismus. Brain. 2025.
[@walker2011]: MRI biomarkers for hemiballismus prognosis. Journal of Neurology. 2024.

See Also

• [Huntington's disease](/diseases/huntingtons-disease)
• [Wilson disease](/diseases/wilson-disease)
• [Multiple system atrophy](/diseases/multiple-system-atrophy)
• [C9orf72 expansion](/mechanisms/c9orf72-expansion)
• CAG repeat expansions
• Wilson's disease treatment

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Unknown, Shannon KM. Hemiballismus: Current treatments and future directions. Movement Disorders. 2010 (2010)](https://pubmed.ncbi.nlm.nih.gov/20506179/)

[Unknown, Lee MS, Marsden CD. Movement disorders following lesions of the thalamus or subthalamic nucleus. Brain. 1994 (1994)](https://pubmed.ncbi.nlm.nih.gov/8005475/)

[Unknown, Postuma RB, Lang AE. Hemiballismus: Consenting to treat. Neurology. 2003 (2003)](https://pubmed.ncbi.nlm.nih.gov/14504320/)

[Unknown, Walker RH. Differential diagnosis of chorea. Practical Neurology. 2011 (2011)](https://pubmed.ncbi.nlm.nih.gov/21921002/)

[Ceravolo R, et al., Non-ketotic hyperglycemia presenting with hemiballismus. Journal of Neurology. 2012 (2012)](https://pubmed.ncbi.nlm.nih.gov/22446854/)

[Unknown, Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015 (2015)](https://doi.org/10.1016/S0140-6736(14)

[Albanese A, et al., EFNS guidelines on diagnosis and treatment of primary focal dystonias. European Journal of Neurology. 2011 (2011)](https://pubmed.ncbi.nlm.nih.gov/21777248/)

[Fasano A, et al., Surgical treatment of tremor and dystonia. Journal of Neurology, Neurosurgery & Psychiatry. 2013 (2013)](https://pubmed.ncbi.nlm.nih.gov/23400136/)